IRADIMED CORPORATION (IRMD) Earnings Call Transcripts

IRADIMED CORPORATION's Latest Earnings Call - Q1 FY2026

IRADIMED Corporation reported Q1 2026 revenue of $22 million, a 13% increase YoY, driven by strong performance across product lines, notably the MRI compatible IV infusion pump. Net income rose to $5.8 million or $0.45 per diluted share, a 22% increase over the prior year. Management highlighted the successful launch of the new 3870 MR IV pump, with ASPs exceeding expectations. The company maintained its full-year guidance, projecting revenue between $91 million and $96 million, and EPS of $1.90 to $2.05. The focus on the 3870 pump's replacement opportunity is expected to drive growth in the coming quarters.

Reported metrics

Guidance from management

For Q2 2026, IRADIMED expects revenue of $20 million to $21 million and GAAP EPS of $0.40 to $0.44. Full-year guidance is maintained with revenue of $91 million to $96 million and GAAP EPS of $1.90 to $2.05.

What management said

No. That's not the -- pump is, as I said, was high. the net price of the previous pump was 20,000. So let's [indiscernible], right? So the greater spot was 20,000. You can buy the second channel providing to 10. So as we've told many times, our typical ASP pump deal -- it's just under 4 by the time you get the [indiscernible] and all that and the remote and all that. That's where it was landing. So the quad system w...

No. No. What I was speaking about that earlier in the call, I'm just talking taking 1,000 out of the installed base where the old pumps are refill would be extra. And frankly, maybe I probably more clear, but frankly, the excitement well and the customers -- existing customers calling us [indiscernible] see the new pump is it kind of a fancy right now. I don't see that we're going to have time to start calling on the...

What analysts pressed on

Analysts questioned the sustainability of the high ASPs for the 3870 pump and the potential impact of manufacturing constraints on meeting demand. Concerns were also raised about the pace of greenfield expansion given the current focus on replacement sales.

Main topics on the call

• Revenue Growth — Q1 2026 revenue increased by 13% YoY to $22 million, with strong contributions from the MRI compatible IV infusion pump and MR patient monitor. 'These results reflect solid execution across our product lines,' stated CEO...
• 3870 MR IV Pump Launch — The new 3870 MR IV pump's ASP is showing a lift closer to 20% over the historical 3860 pump ASP. Management is optimistic about the replacement opportunity, which will be a key growth driver for the next several years.
• Operating Income — Operating income increased by 33% YoY to $7.2 million, attributed to revenue growth and disciplined expense management.
• Gross Margin Improvement — Gross margin improved to 77% from 76% in Q1 2025, reflecting efficient cost management.

Read the full IRADIMED CORPORATION transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 IRADIMED CORPORATION earnings call transcripts on record, spanning February 6, 2020 to July 31, 2026. Based on this history, IRADIMED CORPORATION reports quarterly. The most recent call on file is dated July 31, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IRMD

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

28

First call

February 6, 2020

Most recent

July 31, 2026

Reporting cadence

quarterly